"Truly evil" FDA rejection of gene therapy overturned after Trump official ousted
The FDA has reopened the approval path for UniQure's gene therapy AMT-130 following the departure of specific Trump-era officials who had previously blocked it. The therapy aims to treat Huntington’s disease, a fatal neurodegenerative condition, by lowering levels of the mutant huntingtin protein.
Why it matters
This case illustrates the intersection of political leadership changes and regulatory decision-making in the pharmaceutical industry, directly impacting patient access to life-saving treatments.
Reversed Truly evil FDA rejection of gene therapy overturned after Trump official ousted Gene therapy company UniQure had another FDA meeting after Vinay Prasad s exit.
The use of emotionally charged language like 'truly evil' and the framing of the FDA rejection as a result of specific political appointees suggests a critical stance toward the previous administration's influence.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in